510(k) · Cleared
Cleared17 B-Estradiol (Elisa)
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Kmi Diagnostics, Inc. · CHP Radioimmunoassay, Estradiol
Cleared on Nov 24, 1997 after a 41-day review. FDA’s file for it is a 510(k) statement, which names no predicate.
- Decided
- Nov 24, 1997
- Review
- 41 days
- Class
- Class I
- Product code
- CHP
- Recalls
- None
- Predicates
- 0
FDA’s file for it is a 510(k) statement, which names no predicate.
Sources: FDA 510(k) database (decision fields), the FDA 510(k) statement (indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in CHP? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
- Candidate predicates for a device like this, rankedin the report
- Recall history across each candidate’s familyin the report
What was it cleared against?
FDA’s file for it is a 510(k) statement, which names no predicate.
What descends from it?
No later submission names this one as a predicate yet.
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
How does its category compare?
All CHP devicesCHP Radioimmunoassay, Estradiol: FDA decisions, review times, recalls and adverse event reports over 20 years.
FDA decisions per year · CHP
FDA has decided no CHP device since 2007.
Median 510(k) review, days · CHP
Too few CHP 510(k)s in any year since 2007 to give a median.
Recalls per year · CHP
7in 2022
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · CHP
84in 2025
MAUDE reports naming product code CHP, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 0 | — | 1 | 0 |
| 2008 | 0 | — | 0 | 1 |
| 2009 | 0 | — | 0 | 9 |
| 2010 | 0 | — | 1 | 12 |
| 2011 | 0 | — | 0 | 10 |
| 2012 | 0 | — | 0 | 15 |
| 2013 | 0 | — | 0 | 4 |
| 2014 | 0 | — | 0 | 12 |
| 2015 | 0 | — | 0 | 18 |
| 2016 | 0 | — | 1 | 29 |
| 2017 | 0 | — | 1 | 39 |
| 2018 | 0 | — | 1 | 38 |
| 2019 | 0 | — | 0 | 36 |
| 2020 | 0 | — | 0 | 135 |
| 2021 | 0 | — | 1 | 43 |
| 2022 | 0 | — | 7 | 61 |
| 2023 | 0 | — | 0 | 60 |
| 2024 | 0 | — | 0 | 65 |
| 2025 | 0 | — | 0 | 84 |
| 2026 | 0 | — | 0 | — |
What is it indicated for?
The IBL Estradiol ELISA test kit is intended for the in vitro determination of cstradiol, an estrogenic steroid, in human serum and piasma. Estradiol measurements are used in the dugnosticsand treatment of various hormonal sexual disorders and in assessing placental function in complicated pregnancy.
Indications for use read by OCR from a scanned FDA 510(k) statement, so letters may be misread. Check the PDF before quoting it.
https://510kreport.com/device/K973901 · printed Nov 5, 2026
Cite this page
510(k) Report. “K973901: 17 B-Estradiol (Elisa).” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 5, 2026. https://510kreport.com/device/K973901
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Page last updated Nov 3, 2026